Information Provided By:
Fly News Breaks for April 30, 2015
VRTX
Apr 30, 2015 | 07:59 EDT
Leerink raised its price target for Vertex to $150 saying it believes the company is best positioned to to establish a dominant franchise in cystic fibrosis. The firm keeps an Outperform rating on the stock following the company's Q1 results.
News For VRTX From the Last 2 Days
VRTX
Apr 23, 2024 | 05:33 EDT
Vertex Pharmaceuticals and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex's cell therapies for type 1 diabetes, or T1D. TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies. TreeFrog's proprietary technology platform, C-Stem, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.